Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPL | P40238 | 10/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1803364 | 0.88 | MPL (0.60) | MPLHSD17B10ALDH1A1RAB9AALOX5 | |
| SCHEMBL1800641 | 0.83 | MPL (0.53) | MPLHSD17B10ALDH1A1RAB9AALOX5 | |
| SCHEMBL1800573 | 0.81 | MPL (0.55) | MPLHSD17B10ALDH1A1RAB9AALOX5 | |
| SCHEMBL474653 | 0.79 | MPL (0.75) | MPLHSD17B10ALDH1A1RAB9AALOX5 | |
| SCHEMBL1801542 | 0.75 | MPL (0.56) | MPLHSD17B10ALDH1A1RAB9AALOX5 | |
| SCHEMBL474197 | 0.75 | MPL (0.78) | MPLHSD17B10ALDH1A1RAB9AALOX5 | |
| SCHEMBL474161 | 0.75 | MPL (1.00) | MPLHSD17B10ALDH1A1RAB9AALOX5 | |
| SCHEMBL128039 | 0.75 | MPL (1.00) | MPLHSD17B10ALDH1A1RAB9AALOX5 | |
| SCHEMBL1800719 | 0.74 | MPL (0.65) | MPLHSD17B10ALDH1A1RAB9AALOX5 | |
| SCHEMBL20267659 | 0.74 | ADORA3 (0.40) | MPLALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2411395-B1 | FUROPYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS SA (CH) | 2013-05-29 | — | — | EP | disclosed |
| US-20120178766-A1 | FUROPYRIMIDINEDIONE DERIVATIVES AS TRPAI MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-07-12 | — | — | US | disclosed |
| US-20120178766-A1 | FUROPYRIMIDINEDIONE DERIVATIVES AS TRPAI MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-07-12 | — | — | US | disclosed |
| US-7951814-B2 | Quinazolinedione derivatives as TRPA1 modulators | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2011-05-31 | — | — | US | disclosed |
| US-7951814-B2 | Quinazolinedione derivatives as TRPA1 modulators | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2011-05-31 | — | — | US | disclosed |
| US-7951814-B2 | Quinazolinedione derivatives as TRPA1 modulators | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2011-05-31 | — | — | US | disclosed |
| WO-2010004390-A1 | QUINAZOLINE DIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2010-01-14 | — | — | WO | disclosed |
| WO-2010004390-A1 | QUINAZOLINE DIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2010-01-14 | — | — | WO | disclosed |
| US-20090325987-A1 | QUINAZOLINEDIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2009-12-31 | — | — | US | disclosed |
| US-20090325987-A1 | QUINAZOLINEDIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2009-12-31 | — | — | US | disclosed |
| US-20090325987-A1 | QUINAZOLINEDIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178766-A1 | FUROPYRIMIDINEDIONE DERIVATIVES AS TRPAI MODULATORS | TRPA1, TRPV1, TRPC3 | MPL 3150/4885HSD17B10 3242/4885ALDH1A1 449/4885 |
| US-20090325987-A1 | QUINAZOLINEDIONE DERIVATIVES AS TRPA1 MODULATORS | TRPA1, TRPV1, TRPC3 | MPL 4421/4885HSD17B10 2398/4885ALDH1A1 871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.